Private Equity Driving Dynamic CRO Growth

By CenterWatch
Published: November 2015

Private equity (PE), which has been very active in the CRO space over the past five years, is reshaping the CRO landscape—giving the industry financial stability it might not otherwise have and providing the capital for CROs to expand, both organically and inorganically, to offer a broader range of services and greater efficiency to support R&D operations. PE has changed the look of the industry over the past 10 years. It has added a level of credibility to the space by being willing to buy an asset like a CRO. As sponsors look to outsource their R&D operations to a smaller number of integrated and strategic partners, PE gives the ability to develop long-term strategies that better integrate drug development services and improve R&D innovations.

To learn more register for our free white paper Private Equity Driving Dynamic CRO Growth.

Please enter in your information below. Fields with an * are required.

Please enter a valid email address to receive an email with a link to download the white paper.   

Please check the types of email communications you would like to receive:

CenterWatch offers a range of white papers for download that investigate and analyze current trends in the clinical trials industry and the impact they have on the research community.

Recent titles from CenterWatch:

Mobile health picks up momentum

Lack of clinical data overshadows opioid prescribing guidelines

CROs begin consolidating site landscape